Background: rVIII-SingleChain, a novel recombinant factor VIII (rFVIII), has been designed as a B-domain truncated construct with covalently bonded heavy and light chains, aiming to increase binding affinity to von Willebrand factor (VWF). Preclinical studies confirmed greater affinity for VWF, giving improved pharmacokinetic and pharmacodynamic properties compared with full-length rFVIII. Aim: To investigate the pharmacokinetics of rVIII-SingleChain and compare them against those of full-length rFVIII. Methods: This study enrolled 27 patients with severe haemophilia A in the AFFINITY clinical trial programme. After a 4-day washout period, all patients received a single infusion of 50 IU kg À1 octocog alfa (Advate â ); after a ≥4-day postinfusion washout period, they received a single infusion of 50 IU kg À1 rVIII-SingleChain. Blood samples for pharmacokinetic assessments of each product were collected before infusion (predose) and at 0.5, 1, 4, 8, 10, 24, 32, 48 and 72 h postinfusion for both products. Results: rVIII-SingleChain had a longer mean half-life (t 1/2 ) (14.5 vs. 13.3 h), lower mean clearance (CL) (2.64 vs. 3.68 mL h À1 kg
Introduction
The two most important complications of factorreplacement therapy in haemophilia A today are breakthrough bleeds during prophylaxis and the development of inhibitors. Furthermore, frequent factor VIII (FVIII) injections impact on the quality of life of affected individuals and their adherence to treatment. New recombinant FVIII (rFVIII) products have been developed to extend the half-life (t 1/2 ) of FVIII through chemical modification (e.g. glycoPEGylation) or fusion with Fc fragments [1, 2] . Despite these manipulations, the extension of rFVIII t 1/2 has been modest, limited to approximately 1.6-fold higher than that of full-length rFVIII (FL-rFVIII) [3, 4] . The t 1/2 extension of the modified rFVIII seems to be dependent upon the plasma t 1/2 of von Willebrand factor (VWF).
rVIII-SingleChain, a novel rFVIII, has been designed as a B-domain truncated construct with covalently bound heavy and light chains, aiming for a higher binding affinity with VWF [5] . Preclinical studies confirmed a high affinity for VWF, with improved pharmacokinetic (PK) and pharmacodynamic properties vs. FL-rFVIII [6] . These studies indicated that exposure to rVIII-SingleChain is greater than for FL-rFVIII at equal doses, without the need for PEGylation or fusion with other proteins. In vitro studies suggest that, in addition to protecting FVIII from proteolysis, VWF limits rFVIII recognition by antigen-presenting cells, which may reduce the risk of inhibitor development [7, 8] . Further, preclinical studies have demonstrated the efficacy and safety of this novel molecule in mice, rabbits and non-human primates [9] .
This PK investigation was part of an ongoing phase I/III clinical study [10] within the AFFINITY clinical trial programme. Here, we report the PK, safety and tolerability of rVIII-SingleChain compared with FLrFVIII in 27 adult patients with severe haemophilia A.
Methods

Patients
This study recruited 27 male patients (18-65 years old) with severe haemophilia A and ≥150 exposure days to FVIII-containing products with no history of inhibitors. After a 4-day washout period, all patients received a single infusion of octocog alfa (Advate â , Baxter Healthcare Corporation, CA, USA) at a dose of 50 IU kg
À1
, based on the potency defined by the US label. They then received a single infusion of 50 IU kg À1 rVIII-SingleChain ≥4 days after the octocog alfa infusion. Blood samples for PK assessments were collected before infusion (predose) and at 0.5, 1, 4, 8, 10, 24, 28, 48 and 72 h postinfusion for each product. The 28-h postinfusion PK sampling was included in the original protocol but was replaced with PK sampling at 32 h, following a request from the US Food and Drug Administration. Consequently, the first three patients enrolled in the study had a 28-h sample collection; the remaining patients had a 32-h sample collection (Fig. 1) . This study was performed in accordance with the US Code of Federal Regulations and International Conference on Harmonisation Guidelines on Good Clinical Practice. Approval from participating institutional review boards and written informed consent from all patients were obtained in accordance with the Declaration of Helsinki.
Chromogenic substrate assay
FVIII activity in plasma samples was determined with a chromogenic assay, performed in CSL Behring's Central Laboratory (Marburg, Germany) using the Coamatic â test kit (Chromogenix, Essen, Germany), following the manufacturer's instructions, using the Behring Coagulation System (Siemens Healthcare Diagnostics, Marburg, Germany). Separate methods were used to determine the normal and low ranges of FVIII activity [lower limit of quantification (LLOQ) 1 IU dL À1 ]; the principal differences were sample volume and the predilution ratio. Accuracy, precision, repeatability, linearity, range and robustness were validated by predefined criteria. Reference curves were prepared from standard human plasma (SHP) calibrated by the manufacturer against World Health Organization (WHO) standard material for plasma.
Determination of FVIII inhibitors
FVIII inhibitors were assessed using the Nijmegenmodified Bethesda assay [11] . Equal volumes of plasma sample (with and without dilution in FVIIIdepleted plasma) and a standardized normal citrated plasma pool containing FVIII (e.g. SHP from Siemens N = 27 Healthcare Diagnostics) were mixed and incubated for 2 h at 37°C. FVIII activity was then measured by a one-stage assay using Pathromtin â SL (Siemens Healthcare Diagnostics, Marburg, Hesse, Germany). Residual activity in the patient sample was calculated and converted to Bethesda units using a theoretical curve or mathematical function [12] . The assay was validated for linearity, LLOQ and robustness in human plasma samples and met predefined criteria. Samples for FVIII inhibitor testing were taken at screening and at 72 h postinfusion of rVIII-SingleChain.
Determination of antidrug antibodies against rVIIISingleChain
A screening assay and confirmatory assays were employed to determine antidrug antibodies (ADAs) in the AFFINITY clinical trial programme. For the screening assay, a direct-binding enzyme-linked immunosorbent assay (ELISA) was performed to detect ADAs in clinical samples. If the screening assay was above the cut-off, samples were retested using two direct-binding ELISAs to confirm the specific antibody signal by identifying the immunoglobulin (Ig) isotype (IgG or IgM). If the confirmatory assays were negative, the screening result was considered a false positive. If either confirmatory assay was positive, the final result was reported as positive. Samples were taken at screening, prior to rVIII-SingleChain administration and at 72 h postinfusion of rVIII-SingleChain.
VWF antigen determination
For VWF antigen determination, a commercially available test kit purchased from Siemens Healthcare Diagnostics was used. A specific antibody to VWF was bound covalently to polystyrene particles, which aggregated when mixed with samples containing VWF antigen. VWF antigen was then measured turbidimetrically using the Behring Coagulation System device (Siemens Healthcare Diagnostics) and calibrated against SHP, which was calibrated against WHO standard 97/586 by the manufacturer.
PK assessment
A non-compartmental PK analysis of plasma FVIII activity was performed for individual patient plasma FVIII activity vs. time data using Model 202 for constant infusion in WinNonlin â 6.3.0 (Phoenix Build 6.3.0.395, Pharsight Corp, St Louis, MO, USA), following octocog alfa and rVIII-SingleChain infusion. Only central laboratory FVIII activities, quantified using validated one-stage clotting and chromogenic substrate assays, were used in the analysis. As FVIII is an endogenous protein, this analysis was performed with and without correction for baseline plasma FVIII activity by subtracting immediate predose activity (determined for each product specifically) from that obtained at each timepoint.
Although all enrolled patients had confirmed endogenous FVIII levels of <1%, residual FVIII activities introduced from previous FVIII administrations could have resulted in unexpectedly high predose FVIII activity, potentially introducing baseline overcorrection bias, which would be most pronounced at later timepoints. To minimize overcorrection bias, the presented PK parameters derived from overall PK profiles [area under the plasma concentration vs. time curve (AUC), t 1/2 , clearance (CL), volume of distribution at steady state (V ss ) and mean residence time (MRT)] should be interpreted using baseline-uncorrected values. PK parameters derived primarily from early PK timepoints [maximum observed FVIII concentration (C max ) and incremental recovery (IR)] are best reflected by baseline-corrected values.
Actual sampling times, doses (according to the corresponding potency of specific lot numbers and injection volumes) and injection durations were used for calculations of PK parameters: C max , time to C max , t 1/2 , CL, V ss , AUC from time zero to last quantifiable FVIII activity (AUC 0-last ), AUC from time zero extrapolated to infinity (AUC inf ), MRT and IR.
rVIII-SingleChain potency was assigned using the chromogenic substrate assay calibrated against the WHO standard for FVIII concentrates. Octocog alfa potency was adjusted based upon the chromogenic substrate assay.
Safety assessment
Safety was assessed using the following variables:
• Development of inhibitors against FVIII • Nature and incidence of adverse events • Development of non-inhibitory ADAs against rVIII-SingleChain
• Laboratory-based safety parameters (haematology and biochemistry)
• Vital signs and physical examination • Clinical signs of thrombosis • Local tolerability as assessed by the investigator using predefined criteria.
Statistical analyses
Statistical analyses were conducted by a Contract Research Organization under the supervision of CSL Behring. The CSL lead statistician for the AFFINITY program was responsible for the statistical analyses. SAS (Statistical Analyses System, Cary, NC, USA) software was used. Baseline-uncorrected and -corrected analyses were performed. PK parameters (log-transformed C max , AUCs and CL) were compared using a paired t-test, except for T max which was compared using a Wilcoxon signed-rank test. A sensitivity analysis, in which patients with baseline FVIII activity >1% were excluded, was performed on baseline-uncorrected data.
Results
FVIII activity-based PK parameters were calculated for all 27 patients [all male; mean age 35.4 (range 19-60) years]. Eleven patients were enrolled from Germany, nine from the USA, four from Italy and three from Austria. All patients were of Caucasian ethnicity except for two who were of African American ethnicity. Mean weight was 77.86 (range 59-100) kg and mean body mass index was 24.71 (range 18.7-30) kg m
À2
. All patients met the criteria for severe haemophilia A (historical FVIII activity levels <1%). Of the 27 subjects, 13 received on-demand therapy prior to enrolment and 14 subjects were on routine prophylaxis prior to study entry. No patient received treatment for a bleed during the PK sampling period or experienced any major protocol deviation that might interfere with PK assessment; all patients were included in the PK analysis.
Evaluation of FVIII activity profile in plasma following a single intravenous administration of octocog alfa or rVIII-SingleChain ) before rVIII-SingleChain dosing. After rVIII-SingleChain administration, peak FVIII activities were observed at the first PK sampling (0.5 h postdose). Thereafter, plasma FVIII activity levels decreased exponentially (Fig. 2) . FVIII activities in plasma after octocog alfa administration, also peaked at the first PK sampling (0.5 h postdose), and declined exponentially (Fig. 2) . Of note, FVIII activities at 48 h were >1% in all patients after rVIII-SingleChain dosing while the activity levels in some (2 out of 27) were <1% after octocog alfa dosing.
PK evaluation of FVIII activity in plasma
Baseline-uncorrected FVIII activity PK of rVIII-SingleChain vs. octocog alfa (after dose adjustment). rVIIISingleChain had a longer mean t 1/2 (14.5 vs. 13 ; P <0.0001) than octocog alfa (Table 1 and Fig. 3 ). Mean AUC inf after rVIIISingleChain dosing was approximately 35% higher than after octocog alfa dosing. A similar pattern was observed for AUC 0-last .
As several patients had baseline FVIII activity >1% (incomplete washout) before infusion, a sensitivity analysis was performed with those patients excluded. Differences between rVIII-SingleChain (n = 22) and octocog alfa (n = 21) remained present in this analysis. For example, CL (standard deviation) was 2.76 (0.88) vs. 4.02 (1.41) mL h À1 kg À1 for rVIII-SingleChain and octocog alfa, respectively; AUC inf (standard deviation) was 2010 (683) vs. 1410 (518) IU·h dL À1 for rVIII-SingleChain and octocog alfa, respectively.
Baseline-corrected PK of rVIII-SingleChain vs. octocog alfa (after dose adjustment). PK parameters (C max and IR) derived from early timepoints are best estimated by the baseline-correction approach. , respectively) ( Table 1) .
The baseline-corrected mean t 1/2 of rVIII-SingleChain (14.0 h) was comparable to the baseline-uncorrected value, while the mean t 1/2 of octocog alfa decreased to 11.6 h with baseline correction (14.0 vs. 11.6 h; P = 0.0004). Similar to the baseline-uncorrected FVIII activity, rVIII-SingleChain continued to have a lower mean CL (2.69 vs. ; P <0.0001) compared with octocog alfa (Table 1) . Mean AUC inf after rVIII-SingleChain dosing was~35% higher than that observed after octocog alfa dosing. Within-patient differences in t 1/2 between octocog alfa and rVIII-SingleChain are Octocog alfa (n = 27) rVIII-SingleChain (n = 27) P-values Octocog alfa (n = 27) rVIII-SingleChain (n = 27) P-values depicted in Fig. 4 . The majority of patients had an increased t 1/2 following rVIII-SingleChain dosing compared to octocog alfa. An exploratory post hoc subanalysis of the PK data (all 27 patients) compared both t 1/2 and CL with VWF antigen levels in individual patients. Both octocog alfa and rVIII-SingleChain showed a positive correlation between t 1/2 and VWF antigen and a negative correlation between CL and VWF antigen (Fig. 5) .
Safety
No patient developed inhibitory antibodies against FVIII or antibodies against rVIII-SingleChain by the end of the study. Of the 27 patients, 26 entered the treatment phase of the study and remained inhibitor/ ADA free.
No serious adverse events were reported. Adverse events were recorded in one octocog alfa-treated patient (back pain and musculoskeletal pain, mild and moderate intensity, respectively, not considered to be study drug-related) and two rVIII-SingleChain-treated patients (toothache, mild intensity, not considered to be study drug-related; generalized feeling of being hot, mild intensity, considered to be study drug-related). All events resolved. No vital sign abnormalities were associated with rVIII-SingleChain or octocog alfa infusion.
There was one spontaneous bleeding event (haematuria) that became apparent during rVIII-SingleChain treatment, which did not require additional treatment. Another patient had a nasal bleed, lasting 15 min that did not require treatment and resolved before octocog alfa administration. No local reactions of erythema, itching, pain, heat, measurable oedema or induration were reported after administration of octocog alfa or rVIII-SingleChain.
Discussion
rVIII-SingleChain demonstrated improved PK parameters compared with octocog alfa, exhibiting lower CL, longer t 1/2 , higher MRT and larger AUC. At 50 IU kg À1 , rVIII-SingleChain provided similar peak FVIII activity (IR and C max ), and approximately, 35% higher AUC compared with octocog alfa. To minimize overcorrection bias, AUC, CL, V ss , t 1/2 and MRT have been interpreted using baseline-uncorrected values. Baseline-corrected values are more meaningful for C max and IR and have therefore been used.
Intravenous administration of rVIII-SingleChain was well tolerated in patients with severe haemophilia A. No serious adverse events were observed and all adverse events resolved. All adverse events were mild to moderate, and typical for a population with severe haemophilia A. One mild adverse event of a generalized feeling of being hot was considered to be related to rVIII-SingleChain.
rVIII-SingleChain has been designed as a B-domain truncated construct with covalently bonded heavy and light chains, with the goal of achieving higher FVIII affinity for its chaperone protein VWF. In vitro data show rVIII-SingleChain has an approximately threefold higher affinity for VWF compared with FL-rFVIII [6] , and a greater affinity for VWF than that previously reported for either NovoEight â or human cell line-derived rhFVIII [13] . This single-chain design is unique among currently marketed and developed rFVIII products, which all have a two-chain structure. The two-chain design is also more labile in the manufacturing environment and can result in inactive dissociated FVIII chains being present in the final drug product [14] . Indeed, the unique rVIII-SingleChain design results in enhanced molecular stability and improved structural integrity of the FVIII molecule. One specific class of technologies that have generated considerable interest within the haemophilia community are those for extending t 1/2 , with two products having been approved and several new compounds having completed or entering late-phase clinical trials. In haemophilia B, fusion of factor IX to albumin or Fc antibody fragments [15] results in a marked extension of plasma t 1/2 [16] . Attempts to prolong the t 1/2 of FVIII have been less successful, and FVIII plasma t 1/2 has yet to exceed that of VWF, which seems to limit the survival of current FVIII constructs.
Although comparisons between data obtained from different studies must be made cautiously, fusion of FVIII with an Fc fragment extended the t 1/2 of FVIII to 18.8 h from 11.0 h and increased the AUC to 2800 IUÁh dL À1 from 1800 IUÁh dL À1 at a dose of 65 IU kg À1 [17] . [19] . Clinical experience with these new FVIII products will show if the achieved modest increases in t 1/2 will translate into a benefit for patients, offsetting the need for PEGylation or Fc fusion.
In this study, the t 1/2 of rVIII-SingleChain was prolonged to 14.5 h and the AUC increased to 2090 IUÁh dL À1 at a dose of 50 IU kg
À1
, without requiring major molecular modifications such as fusion to antibody fragments or glycoPEGylation, which may hypothetically alter biological function. These differences remained after excluding data from patients with high baseline FVIII activity levels. Prophylactic dosing intervals for patients with haemophilia A are largely driven by maintaining FVIII activity >1% as the time spent with FVIII activity below a trough of 1% increases the risk of serious bleeding [20] . A recent study has reported that after injection of 50 IU kg À1 rFVIIIFc, the time taken for FVIII activity to fall to 1% was 4.9 days [4] ; in line with this observation, the estimated time to FVIII activity of 1% was approximately 4.25 days after the administration of rVIII-SingleChain.
While t 1/2 calculations can be biased by blood sample timing, CL appears less affected and offers a more robust parameter for comparison of the PK of FVIII products. In a study comparing octocog alfa and N8 an approximate 35% increase in AUC for rVIII-SingleChain compared with octocog alfa. Consistent with the protection against degradation that VWF confers upon FVIII [22] , the observed correlations between VWF antigen levels and t 1/2 and CL of rVIII-SingleChain suggest that increased binding of rVIII-SingleChain to VWF contributes to the improved PK profile compared with octocog alfa. This hypothesis is supported by noting that under physiologic conditions,~1% of FVIII molecules circulate freely while the remaining 99% are VWF bound, but in patients treated with rVIII-SingleChain, the VWF bound fraction increases to 99.9% [6] . Binding of FVIII to VWF also limits its recognition and uptake by antigen-presenting cells, dose-dependently blocking endocytosis of FVIII by monocyte-derived dendritic cells [23] , giving a potential mechanism for mitigating the risk of inhibitor development [7, 8] . This study suggests increased affinity for VWF improves the PK of FVIII, and although no patient developed inhibitors, long-term clinical data, including data from previously untreated patients, are required for establishing the effects of increased VWF binding on immunogenicity.
The favourable PK parameters of rVIII-SingleChain relative to octocog alfa suggest prophylactic rFVIII treatment intervals could be extended, reducing treatment burden and improving patient adherence. Coupled with its high affinity for VWF and potentially reduced immunogenicity, rVIII-SingleChain could address several unmet needs. Future studies will show whether these properties translate into significant clinical benefits.
